Novacyt (NCYT.L): New respiratory disease diagnostic developed | Genedrive (GDR.L): NHS Ethics approval for use of test in hospital trials | e-therapeutics (ETX.L): Interim results for six months ended 31 July 2019
07 Oct 2019
SP Angel Healthcare Conditions
Novacyt SAS (NCYT:LON), 68.1 | Genedrive Plc (GDR:LON), 5.6 | e-Therapeutics plc (ETX:LON), 9.3 | Genedrive Plc (D6M:BER), 0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SP Angel Healthcare Conditions
Novacyt SAS (NCYT:LON), 68.1 | Genedrive Plc (GDR:LON), 5.6 | e-Therapeutics plc (ETX:LON), 9.3 | Genedrive Plc (D6M:BER), 0
- Published:
07 Oct 2019 -
Author:
Vadim Alexandre | Liam Gascoigne-Cohen -
Pages:
4
Novacyt (NCYT.L): New respiratory disease diagnostic developed | Genedrive (GDR.L): NHS Ethics approval for use of test in hospital trials | e-therapeutics (ETX.L): Interim results for six months ended 31 July 2019